ImmunityBio (IBRX) Other Accumulated Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Other Accumulated Expenses data on file, last reported at $2.4 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $2.4 million, down 7.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 7.58% YoY), and the FY2025 annual result was $3.1 million, up 192.67% from the prior year.
• Other Accumulated Expenses fell to $2.4 million in Q1 2026 per IBRX's latest filing, from $3.1 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $3.1 million in Q4 2025 and troughed at $556000.0 in Q1 2024.
• A 5-year average of $1.6 million and a median of $1.5 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses plunged 65.82% in 2023, then surged 376.8% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $1.6 million in 2022, then slumped by 56.02% to $716000.0 in 2023, then soared by 46.65% to $1.0 million in 2024, then soared by 192.67% to $3.1 million in 2025, then dropped by 20.27% to $2.4 million in 2026.
• Business Quant data shows IBRX's Other Accumulated Expenses at $2.4 million in Q1 2026, $3.1 million in Q4 2025, and $2.1 million in Q3 2025.